LSD Interactions

A

  • Alcohol - diminished the effects of alcohol; no differences in the subjective effects of LSD were associated with alcohol use

  • Amitriptyline - potential intensified effects; consider tapering and discontinuing at least 2 weeks prior

  • Azacyclonol - reduced the psychological effects of LSD; hallucinogenic effects of LSD were abolished by pretreatment; one subject was administered 40 mg azacyclonol intravenously at the fifth hour post-LSD ingestion, reported decreased anxiety and decreased psychological effects; no evidence of LSD-blocking effects by azacyclonol was observed; no evidence of azacyclonol effects in changing the effects of LSD; no reduction of any aspect of the LSD reaction

B

  • Bupropion - loss of effect not predicted to occur

  • Buspirone - loss of psychedelic effect; consider tapering and discontinuing at least 5 days prior

C

  • Chlorpheniramine - potential intensified effects; consider tapering and discontinuing at least 2 weeks prior

  • Chlorpromazine - significantly reduced mental, hallucinations, visual perception distortion, anxiety, and pupillary reactions to LSD; elevated the threshold dose of LSD; enhanced positive responses to LSD, reduced anxiety symptoms; increased anxiety and intensified effects of LSD

  • Citalopram - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Clomipramine - earlier onset of LSD effect, increased physical and hallucinatory as well as psychological effects; consider tapering and discontinuing at least 2 weeks prior

D

  • Desipramine - experienced earlier onset of LSD effects and increased hallucinatory as well as psychological effects; consider tapering and discontinuing at least 2 weeks prior

  • Desvenlafaxine - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Duloxetine - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

E

  • Escitalopram - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

F

  • Fluoxetine - markedly decreased sensitivity to LSD; delayed onset of LSD; markedly diminished hallucinogenic and psychological effects as well as overall response of LSD; consider tapering and discontinuing at least 6 weeks prior

  • Fluvoxamine - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

H

  • Hexahydrocannabinol (HHC) - potential increased effects and prolonged duration of LSD ***anecdotal***

I

  • Imipramine - earlier onset of LSD effects and increased hallucinatory as well as psychological effects; consider tapering and discontinuing at least 2 weeks prior

  • Iproniazid - no change to the physical or subjective effects of LSD

  • Isocarboxazid - attenuated psychological, autonomic, and neurologic responses of LSD including blood pressure, heart rate, sensory, and motor functions; potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

K

  • Ketanserin - fully blocked the subjective and mental effects of LSD; less intense subjective experience including less audio-visual synesthesia, 5D-ASC elementary imagery, and experience of unity; blocked subjective drug effects, ego dissolution, anxiety, and oceanic boundlessness score; administration of ketanserin after the effects of LSD has reversed subjective and autonomic responses to LSD in humans, with reduced LSD duration; did not alter overall mystical experiences or reverse the LSD-induced increase of plasma BDNF, or alter the pharmacokinetics of LSD

L

  • Levomilnacipran - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Lithium - earlier onset as well as increased hallucinatory and psychological effects of LSD

M

  • MDMA - higher plasma concentrations and extended plasma elimination half-life for LSD with longer psychedelic experiences, and increased blood pressure and heart rate compared to LSD alone

  • Mirtazapine - loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Moclobemide - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

N

  • Niacin - pretreatment delayed the onset of LSD effects and prevented most of the perceptual changes from occurring; administration post-LSD ingestion attenuated all effects of LSD and markedly diminished the proprioceptive, perceptual, cognitive, and motor effects of LSD

  • Nialamide - blocked reactions to LSD

  • Nortriptyline - potential intensified effects; consider tapering and discontinuing at least 2 weeks prior

P

  • Paroxetine - attenuated the hallucinogenic as well as physiologic effects of LSD and overall, reduced responses to LSD; consider tapering and discontinuing at least 2 weeks prior

  • Phenelzine - nearly abolished the subjective responses of LSD including hallucination and psychological effects; potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Phenoxybenzamine - did not alter LSD-induced effects on pulse rate, blood pressure, or subjective clinical effects

R

  • Reserpine - enhanced the effects of LSD on autonomic and neurologic responses as well as psychological reactions to LSD; intensified LSD effects of nervousness and confusion, including nasal stuffiness, nausea, diarrhea, vomiting, and lethargy in a dose-dependent manner; intensified LSD effects; enhanced the physical effects of LSD including prolonged tremors and akathisia, effects were ‘unpleasant’ and lasted longer

S

  • Scopolamine - did not alter LSD-induced effects on patellar reflex, pupil size, blood pressure, or subjective clinical effects

  • Selegiline - intensified effects possible, possible risk of serotonin syndrome; potential low risk of physical toxicity; consider tapering and discontinuing at least 2 weeks prior

  • Sertraline - decreased physical, hallucinogenic, and psychological effects of LSD; consider tapering and discontinuing at least 2 weeks prior

T

  • Tranylcypromine - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Trazodone - reduced hallucinogenic and physiological effects of LSD as well as overall response of LSD; loss of psychedelic effect; consider tapering and discontinuing at least 5 days prior

V

  • Venlafaxine - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Vilazodone - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

  • Vortioxetine - potential loss of psychedelic effect; consider tapering and discontinuing at least 2 weeks prior

LSD

DMT